Nuclisome—targeting the tumor cell nucleus

Gedda, Lars; Edwards, Katarina

doi:10.1007/s13277-012-0341-3

Cited by 3 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A unique strategy to develop liposomes targeting the nucleus is the nuclisome particles concept comprised of a two-step targeting strategy that aims to deliver short-range Auger-electron-emitting radionuclides to nuclear DNA of tumor cells [102]. Here, PEG-stabilized liposomes loaded with a unique DNA-intercalating compound were targeted to tumor cells to promote the delivery of radionuclides to DNA.…”

Section: Organelle-specific Targetingmentioning

confidence: 99%

Current Trends in The Use of Liposomes for Tumor Targeting

2013

View full text Add to dashboard Cite

The use of liposomes for drug delivery began early in the history of pharmaceutical nanocarriers. These nanosized, lipid bilayered vesicles have become popular as drug delivery systems owing to their efficiency, biocompatibility, nonimmunogenicity, enhanced solubility of chemotherapeutic agents and their ability to encapsulate a wide array of drugs. Passive and ligand-mediated active targeting promote tumor specificity with diminished adverse off-target effects. The current field of liposomes focuses on both clinical and diagnostic applications. Recent efforts have concentrated on the development of multifunctional liposomes that target cells and cellular organelles with a single delivery system. This review discusses the recent advances in liposome research in tumor targeting.

show abstract

Section: Organelle-specific Targetingmentioning

confidence: 99%

Current Trends in The Use of Liposomes for Tumor Targeting

2013

View full text Add to dashboard Cite

show abstract

“…Furthermore, when the nuclisomes targeted to HER2 were given to mice carrying human ovarian cancer xenografts, they accumulated in the tumors and there was a significant difference between treated and mock treated animals since more than 50% of the surviving mice were tumor-free. In addition, no macroscopic or microscopic radiotoxic side effects were observed in the mice (31,57,58) supporting the nuclisome approach in specific also in vivo and the feasibility of the AE-based radiotherapy in general.…”

Section: Nanoparticlesmentioning

confidence: 59%

Novel radioisotope-based nanomedical approaches

Olsen¹,

Thisgaard²,

Vogel

et al. 2013

European Journal of Nanomedicine

View full text Add to dashboard Cite

Radioisotope therapy of cancer is on the rise applying mainly β-emitting radionuclides. However, due to exposure of healthy tissues, the maximum achievable radiation dose with these is limited. Auger-electron emitters (AEs) represent a promising alternative because of their mode of decay within a short nanometer range. The challenge is that their therapeutic efficacy relies on a close vicinity to DNA. To overcome this and to minimize toxicity, the construction of smart nanomedical devices is required, which ascertain tumor cell targeting with succeeding cellular uptake and nuclear translocation. In this review we describe the potential of AEs with focus on their delivery down to the DNA level and their cellular effects. Reported efforts comprise different tumor-targeting strategies, including the use of antibodies or peptides with nuclear localizing sequences. Recently, attention has shifted to various nanoparticle formats for overcoming delivery problems. To this end, these approaches have mostly been tested in cell lines in vitro applying AEs more suited for imaging than therapy. This defines a demand for nanomedical formulations with documented in vivo activity, using AEs selected for their therapeutic potential to come closer to real clinical settings.

show abstract